Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma

Enzastaurin in patients with follicular lymphoma: Results of a phase II study.

(2017) L. Schwartzberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma.

(2017) N. H. Fowler et al.   JOURNAL OF CLINICAL ONCOLOGY

Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies

(2011) Loic Ysebaert et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Signal Transduction Inhibitor Therapy for Lymphoma

(2011) T. E. Witzig et al.   Hematology-American Society of Hematology Education Program

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines

(2010) Monica Civallero et al.   LEUKEMIA & LYMPHOMA

Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context

(2010) W.-L. Kuo et al.   MOLECULAR CANCER THERAPEUTICS

Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century

(2008) Dianne Pulte   ARCHIVES OF INTERNAL MEDICINE

Molecular targeting of the PKC-βinhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression

(2008) Donata Verdelli et al.   HEMATOLOGICAL ONCOLOGY

The oral protein-kinase Cβinhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines

(2008) Antonino Neri et al.   LEUKEMIA & LYMPHOMA

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

(2007) F. Morschhauser et al.   ANNALS OF ONCOLOGY